Overview

A Study in Advanced Cancer

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Ignyta, Inc.